Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.90 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.90 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.90 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.90 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.89 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165997 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL9872231 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL4754501 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL1149378 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL15762968 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL12871334 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL5003539 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL452334 | 1.00 | ITPR3 (0.90) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL113868 | 0.97 | ITPR3 (0.89) | ITPR3ITPR2ITPR1INPP5ASMPD1 | |
| SCHEMBL14396732 | 0.97 | ITPR3 (0.89) | ITPR3ITPR2ITPR1INPP5ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | ITPR3 23/4885ITPR2 21/4885ITPR1 25/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | ITPR3 3071/4885ITPR2 3352/4885ITPR1 3734/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | ITPR3 179/4885ITPR2 103/4885ITPR1 143/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | ITPR3 188/4885ITPR2 110/4885ITPR1 155/4885 |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | SCLY, SMOX, SMS | ITPR3 23/4885ITPR2 21/4885ITPR1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.